Targeting Ferroptosis in Adenocarcinoma of the Esophagogastric Junction: From a Natural Compound to Clinical Translation.

Abstract

Ferroptosis-cell death driven by iron-is gaining traction in oncology. A study published in Current Cancer Drug Targets (CCDT) shows that a natural compound, Macranthoside B (MB), inhibits the activity of Adenocarcinoma of the Esophagogastric Junction (AEG) and that NRF2-mediated ferroptosis is involved in its regulation. This editorial discusses the mechanistic implications of that study, with particular attention to the NRF2/NCOA4-related ferritinophagy axis, while also emphasizing the limitations that should be addressed before clinical translation. Although the findings provide a useful preclinical rationale for exploring ferroptosis-oriented therapeutic strategies in AEG, key questions remain regarding the validation of the causal pathway, pharmacokinetics, systemic toxicity, tumor selectivity, model representativeness, and biomarker-based patient stratification. Therefore, Macranthoside B should currently be viewed as a promising experimental compound rather than a clinically established therapeutic candidate. Further in vivo studies and carefully designed translational investigations are required to determine whether this natural compound can be advanced toward AEG treatment.